PVLA · Palvella Therapeutics, Inc.
Market Cap
$2.18B
Shares
14.41M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,358,952 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $729,037 |
| Shane Olwill | Former Senior Vice President and Chief Development Officer | $705,445 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $2,062,843 |
| Ahmed Mousa | Senior Vice President and Chief Business Officer | $963,967 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $944,191 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,692,917 |
| Tim Demuth | M.D., Ph.D.\ Senior Vice President and Chief Medical Officer | $1,246,462 |
| Hitto Kaufmann | Senior Vice President and Chief Scientific Officer | $876,757 |
| Thomas Bures | Senior Vice President and Chief Financial Officer | $772,644 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,538,829 |
| Hitto Kaufmann | Senior Vice President and Chief Scientific Officer | $548,636 |
| Thomas Bures | Vice President, Finance | $514,544 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $1,593,598 |
| Hitto Kaufmann | Ph.D.\ Senior Vice President and Chief Scientific Officer | $1,101,279 |
| Louis Matis | M.D.\ \ Chief Development Officer | $759,021 |
| Thomas Bures | Vice President, Finance | $476,680 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen S. Yoder | Chief Executive Officer | $2,621,008 |
| Louis Matis | M.D.\ \ Chief Development Officer | $1,124,169 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Matthew Pauls | Class I director | Appointed | 2026-06-30 |
| John Doux, M.D. | Class III Director | Appointed | 2026-06-16 |
| Todd C. Davis | Class III Director | Appointed | 2026-06-16 |
| George M. Jenkins | Class III Director | Appointed | 2026-06-16 |
| John Doux, M.D. | Class III director | Appointed | 2026-04-13 |
| Tom Bures | Acting General Counsel | Resigned | 2024-12-16 |
| Stephen Yoder | President and Chief Executive Officer | Resigned | 2024-12-16 |
| Jeffrey Martini, Ph.D. | Chief Scientific Officer | Appointed | 2024-12-16 |
| Wesley H. Kaupinen | Chief Executive Officer, Founder, President and Director | Appointed | 2024-12-16 |
| Matthew Korenberg | Chief Financial Officer | Appointed | 2024-12-16 |
| Kathleen Goin | Chief Operating Officer | Appointed | 2024-12-16 |
| Thomas Bures | Senior Vice President and Chief Financial Officer of the Company | Terminated | 2024-12-16 |
| Tadd S. Wessel | director of the Company | Appointed | 2024-12-16 |
| George M. Jenkins | director of the Company | Appointed | 2024-12-16 |
| Todd C. Davis | director of the Company | Appointed | 2024-12-16 |
| Elaine J. Heron | the Board | Appointed | 2024-12-16 |
| Maya R. Said, Sc.D. | Board | Resigned | 2024-12-16 |
| Matthew Sherman, M.D. | Board | Resigned | 2024-12-16 |
| Wesley H. Kaupinen | director of the Company | Appointed | 2024-12-16 |
| Peter Kiener, D. Phil. | Board | Resigned | 2024-12-16 |
| Ann Barbier, MD., Ph.D. | Board | Resigned | 2024-12-16 |
| Michael Richman | Board | Resigned | 2024-12-16 |
| James Geraghty | Board | Resigned | 2024-12-16 |
| Stephen Yoder | President and Chief Executive Officer | Terminated | 2024-12-16 |
| Maya R. Said, Sc.D. | Director | Resigned | 2024-12-16 |
Key facts
CIK
1583648
CUSIP
697947109
13F (30d)
175 filings
172 filers
Visit website
Investor relations